IDH1 as prognostic factor in patients with brain tumors

Progression free survival and overall survival of patients with brain tumors dependent on IDH1 mutation, methyltransferase (MGMT) methylation, age, WHO diagnosis and combinations of these factors.
Sample Size
all patients: n=382; anaplastic astrocytoma: n = 145; primary glioblastoma: n = 237

Expression data from cerebral tumors of WHO grade II and III

Molecular profiling of cerebral gliomas distinguishes biologically distinct tumor groups and provides prognostically relevant information beyond histological classification and IDH1/2 mutation status. We performed microarray-based genome- and transcriptome-wide molecular profiling of primary tumor samples from 137 patients with cerebral gliomas, 61 WHO grade II and 76 WHO grade III tumors.

Clinical data from patients with glioblastoma

Progression free survival and overall survival of patients with glioblastoma dependent on TP53 mutation, p53 immunoreactivity, epidermal growth factor receptor, cyclin-dependent kinase CDK 4 or murine double minute 2 amplification, CDKN2A homozygous deletion, allelic losses on chromosome arms 1p, 9p, 10q, and 19q, O6-methylguanine methyltransferase (MGMT) promoter methylation, and isocitrate dehydrogenase 1 (IDH1) mutations
Sample Size